patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_894988 | REC_0016601 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 12.5 | 66 | female | 1 | 16 | 4.3 | 6 | osimertinib 80 mg daily | 10.4 | true | MSS | 2026-03-15T05:36:01.810419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_407882 | REC_0016602 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 14.5 | 64 | male | 1 | 16 | 5.3 | 2 | entrectinib 600 mg daily | 21.2 | false | MSS | 2026-03-15T05:36:01.811058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877012 | REC_0016603 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 15.4 | 84 | female | 2 | 13 | 5.3 | 5 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:36:01.811577+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110487 | REC_0016604 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 24 | 13.1 | 75 | female | 1 | 6 | 5.5 | 2 | osimertinib 80 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:36:01.812048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833728 | REC_0016605 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 3.7 | 84 | male | 3 | 57 | 5 | 4 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:36:01.812620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_995536 | REC_0016606 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 21.3 | 65 | male | 1 | 19 | 5.2 | 5 | entrectinib 600 mg daily | 9.3 | true | MSI-H | 2026-03-15T05:36:01.813022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824169 | REC_0016607 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 12 | 62 | female | 1 | 8 | 5.4 | 1 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:36:01.813409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288110 | REC_0016608 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 14.4 | 73 | female | 2 | 8 | 6 | 4 | osimertinib 80 mg daily | 17.8 | false | MSI-H | 2026-03-15T05:36:01.814093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553106 | REC_0016609 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 12.6 | 66 | female | 1 | 11 | 6 | 2 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:36:01.814533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458688 | REC_0016610 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 11.4 | 56 | female | 1 | 4 | 4.8 | 6 | osimertinib 80 mg daily | 8.2 | false | MSI-H | 2026-03-15T05:36:01.814882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673247 | REC_0016611 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.3 | 60 | male | 0 | 17 | 4.5 | 7 | entrectinib 600 mg daily | 9 | true | MSI-H | 2026-03-15T05:36:01.815242+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999290 | REC_0016612 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 12.4 | 65 | female | 1 | 16 | 4.6 | 6 | pembrolizumab 200 mg q3w | 11.5 | false | MSI-H | 2026-03-15T05:36:01.815646+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467178 | REC_0016613 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11.7 | 56 | female | 0 | 9 | 5.5 | 6 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:36:01.816529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473706 | REC_0016614 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 9.2 | 59 | female | 1 | 16 | 3.8 | 6 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:36:01.816953+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313254 | REC_0016615 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 20.1 | 66 | male | 0 | 14 | 4.6 | 2 | osimertinib 80 mg daily | 29.4 | false | MSS | 2026-03-15T05:36:01.817590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352737 | REC_0016616 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.2 | 62 | male | 1 | 43 | 7.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.7 | false | MSS | 2026-03-15T05:36:01.818048+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406035 | REC_0016617 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 7.9 | 68 | female | 0 | 21 | 5.8 | 7 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:36:01.818443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546336 | REC_0016618 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 9.3 | 43 | female | 0 | 10 | 4.5 | 6 | pembrolizumab 200 mg q3w | 10.7 | true | MSS | 2026-03-15T05:36:01.818813+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399979 | REC_0016619 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 11.2 | 63 | female | 1 | 13 | 4.3 | 1 | alectinib 600 mg BID | 13.7 | true | MSI-H | 2026-03-15T05:36:01.819192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331536 | REC_0016620 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.1 | 73 | female | 2 | 24 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.1 | true | MSS | 2026-03-15T05:36:01.819574+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_999974 | REC_0016621 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.5 | 63 | female | 0 | 4 | 5.8 | 6 | entrectinib 600 mg daily | 9.6 | true | MSI-H | 2026-03-15T05:36:01.819966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340512 | REC_0016622 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 9.2 | 69 | female | 0 | 21 | 7.1 | 5 | sotorasib 960 mg daily | 10.1 | false | MSS | 2026-03-15T05:36:01.820471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_166182 | REC_0016623 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 14 | 12.6 | 44 | male | 0 | 13 | 4.6 | 6 | alectinib 600 mg BID | 10.1 | true | MSI-H | 2026-03-15T05:36:01.820894+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617110 | REC_0016624 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 9.2 | 74 | male | 2 | 14 | 6 | 4 | osimertinib 80 mg daily | 14.2 | true | MSS | 2026-03-15T05:36:01.821358+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_677291 | REC_0016625 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 11.4 | 61 | male | 0 | 11 | 4.4 | 7 | osimertinib 80 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:01.821742+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987055 | REC_0016626 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 35 | 9.4 | 74 | female | 1 | 18 | 4.2 | 0 | osimertinib 80 mg daily | 36.3 | false | MSS | 2026-03-15T05:36:01.822126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760713 | REC_0016627 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 13.6 | 67 | female | 0 | 16 | 4.4 | 1 | alectinib 600 mg BID | 15.8 | false | MSS | 2026-03-15T05:36:01.822511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_351970 | REC_0016628 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 10.8 | 74 | female | 3 | 9 | 5.7 | 2 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:36:01.823086+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126152 | REC_0016629 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 4.8 | 67 | female | 1 | 16 | 4.6 | 1 | pembrolizumab 200 mg q3w | 19.9 | true | MSS | 2026-03-15T05:36:01.823554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_658205 | REC_0016630 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 13.2 | 68 | female | 1 | 1 | 5 | 1 | osimertinib 80 mg daily | 16.8 | false | MSS | 2026-03-15T05:36:01.823950+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176232 | REC_0016631 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12 | 58 | male | 1 | 17 | 5.6 | 4 | entrectinib 600 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:36:01.824452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545068 | REC_0016632 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 6.9 | 69 | female | 1 | 17 | 4.7 | 7 | osimertinib 80 mg daily | 12 | true | MSS | 2026-03-15T05:36:01.824844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_599999 | REC_0016633 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 12.2 | 69 | female | 0 | 19 | 6.7 | 6 | alectinib 600 mg BID | 7.6 | true | MSS | 2026-03-15T05:36:01.825237+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249769 | REC_0016634 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 14.5 | 78 | female | 1 | 28 | 4.5 | 2 | osimertinib 80 mg daily | 25.1 | true | MSI-H | 2026-03-15T05:36:01.825568+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153947 | REC_0016635 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.9 | 75 | female | 1 | 15 | 5.7 | 4 | osimertinib 80 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:36:01.825908+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837972 | REC_0016636 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 8.9 | 69 | male | 0 | 13 | 4.7 | 2 | sotorasib 960 mg daily | 24.2 | true | MSS | 2026-03-15T05:36:01.826284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_473315 | REC_0016637 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 9.8 | 76 | female | 1 | 14 | 7.7 | 5 | entrectinib 600 mg daily | 13.7 | true | MSS | 2026-03-15T05:36:01.826647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444512 | REC_0016638 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 12.8 | 60 | female | 0 | 15 | 5.2 | 2 | entrectinib 600 mg daily | 7 | true | MSI-H | 2026-03-15T05:36:01.827006+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853583 | REC_0016639 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 14.9 | 66 | female | 0 | 9 | 8.3 | 4 | entrectinib 600 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:01.827373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_240017 | REC_0016640 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 3.6 | 57 | male | 0 | 13 | 3.6 | 8 | alectinib 600 mg BID | 14.2 | false | MSS | 2026-03-15T05:36:01.827748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567793 | REC_0016641 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 12.7 | 58 | female | 1 | 13 | 6.2 | 2 | alectinib 600 mg BID | 21.4 | false | MSI-H | 2026-03-15T05:36:01.828331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_716921 | REC_0016642 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 4.1 | 72 | male | 1 | 14 | 6.6 | 3 | entrectinib 600 mg daily | 11.2 | true | MSS | 2026-03-15T05:36:01.828763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967279 | REC_0016643 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.5 | 63 | male | 1 | 26 | 7.4 | 2 | pembrolizumab 200 mg q3w | 15.5 | true | MSS | 2026-03-15T05:36:01.829140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_720771 | REC_0016644 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 5.9 | 76 | female | 1 | 57 | 2.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:36:01.829483+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_814527 | REC_0016645 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 9.7 | 66 | female | 1 | 9 | 4.5 | 5 | entrectinib 600 mg daily | 15.4 | true | MSS | 2026-03-15T05:36:01.829808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_608135 | REC_0016646 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 3.9 | 72 | female | 1 | 27 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 11 | true | MSS | 2026-03-15T05:36:01.830147+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746021 | REC_0016647 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 15.2 | 67 | female | 0 | 13 | 7.6 | 1 | entrectinib 600 mg daily | 14.1 | false | MSI-H | 2026-03-15T05:36:01.830514+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955156 | REC_0016648 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 6.9 | 69 | female | 1 | 20 | 6.7 | 3 | carboplatin + paclitaxel + pembrolizumab | 14.7 | false | MSS | 2026-03-15T05:36:01.830853+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126871 | REC_0016649 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 7 | 82 | female | 2 | 18 | 7.8 | 5 | pembrolizumab 200 mg q3w | 17.1 | false | MSS | 2026-03-15T05:36:01.831194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738920 | REC_0016650 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.2 | 65 | female | 0 | 14 | 3.3 | 7 | entrectinib 600 mg daily | 4.8 | false | MSS | 2026-03-15T05:36:01.831573+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144117 | REC_0016651 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 11.9 | 71 | female | 3 | 6 | 6.7 | 1 | alectinib 600 mg BID | 13.2 | true | MSS | 2026-03-15T05:36:01.831961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334012 | REC_0016652 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 17.5 | 72 | female | 1 | 14 | 7.2 | 0 | alectinib 600 mg BID | 17.7 | true | MSS | 2026-03-15T05:36:01.832430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887101 | REC_0016653 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.4 | 62 | female | 1 | 22 | 4.7 | 5 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:36:01.832842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_850094 | REC_0016654 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 2.5 | 81 | female | 3 | 9 | 7.1 | 1 | entrectinib 600 mg daily | 18 | true | MSS | 2026-03-15T05:36:01.833458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862116 | REC_0016655 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 8.4 | 82 | female | 1 | 18 | 4.8 | 7 | alectinib 600 mg BID | 17 | true | MSS | 2026-03-15T05:36:01.833963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662251 | REC_0016656 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 8.3 | 62 | female | 1 | 17 | 4.8 | 5 | osimertinib 80 mg daily | 17.6 | false | MSS | 2026-03-15T05:36:01.834387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_107667 | REC_0016657 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 9.2 | 74 | female | 2 | 9 | 6.5 | 2 | entrectinib 600 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:01.834741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462849 | REC_0016658 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 11.7 | 77 | female | 1 | 23 | 3.9 | 4 | pembrolizumab 200 mg q3w | 7 | false | MSI-H | 2026-03-15T05:36:01.835153+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_185290 | REC_0016659 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 9.8 | 59 | female | 0 | 14 | 5.6 | 9 | alectinib 600 mg BID | 10 | false | MSS | 2026-03-15T05:36:01.835555+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112356 | REC_0016660 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 3.8 | 69 | female | 1 | 49 | 7.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:01.835927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355568 | REC_0016661 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 8.7 | 66 | female | 0 | 18 | 5.5 | 2 | entrectinib 600 mg daily | 19.2 | true | MSS | 2026-03-15T05:36:01.836362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103391 | REC_0016662 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 9.2 | 58 | male | 0 | 12 | 5.5 | 3 | osimertinib 80 mg daily | 17.2 | true | MSS | 2026-03-15T05:36:01.836773+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254877 | REC_0016663 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 11.6 | 64 | male | 0 | 12 | 4.9 | 6 | entrectinib 600 mg daily | 11.1 | false | MSS | 2026-03-15T05:36:01.837207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672506 | REC_0016664 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 14 | 78 | female | 2 | 13 | 6.5 | 7 | sotorasib 960 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:36:01.837630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564856 | REC_0016665 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 8.8 | 61 | male | 1 | 15 | 5.6 | 4 | alectinib 600 mg BID | 10.1 | false | MSS | 2026-03-15T05:36:01.838063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_921147 | REC_0016666 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 1.5 | 66 | female | 0 | 2 | 5.1 | 0 | osimertinib 80 mg daily | 40 | true | MSS | 2026-03-15T05:36:01.838447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_979296 | REC_0016667 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 27 | 5.7 | 61 | male | 0 | 8 | 7 | 0 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:36:01.838986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_789379 | REC_0016668 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 32 | 14.7 | 65 | male | 0 | 22 | 6.6 | 2 | osimertinib 80 mg daily | 31 | false | MSS | 2026-03-15T05:36:01.839463+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452604 | REC_0016669 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 10.5 | 65 | female | 1 | 26 | 6.8 | 2 | osimertinib 80 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:36:01.839850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939141 | REC_0016670 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.1 | 72 | female | 2 | 18 | 5.5 | 6 | alectinib 600 mg BID | 8.6 | false | MSS | 2026-03-15T05:36:01.840301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_810367 | REC_0016671 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 22 | 8.6 | 72 | female | 2 | 11 | 5.9 | 0 | osimertinib 80 mg daily | 24.1 | true | MSS | 2026-03-15T05:36:01.840714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929102 | REC_0016672 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 15.3 | 60 | female | 0 | 18 | 4.8 | 7 | osimertinib 80 mg daily | 10.6 | true | MSS | 2026-03-15T05:36:01.841128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_669753 | REC_0016673 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 8.3 | 63 | male | 0 | 17 | 5.1 | 1 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:36:01.841587+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656272 | REC_0016674 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 9.8 | 47 | male | 0 | 24 | 7.1 | 2 | alectinib 600 mg BID | 17.7 | false | MSS | 2026-03-15T05:36:01.842009+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_534251 | REC_0016675 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 10.8 | 60 | male | 1 | 14 | 5.5 | 1 | entrectinib 600 mg daily | 24.7 | true | MSI-H | 2026-03-15T05:36:01.842414+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475586 | REC_0016676 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 10.1 | 74 | female | 2 | 13 | 4.8 | 1 | sotorasib 960 mg daily | 27.6 | true | MSS | 2026-03-15T05:36:01.842811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_580276 | REC_0016677 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 7.3 | 70 | female | 2 | 4 | 5.8 | 2 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:36:01.843226+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_260165 | REC_0016678 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.2 | 67 | female | 0 | 43 | 4.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:36:01.843631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762510 | REC_0016679 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 16.7 | 63 | female | 1 | 0 | 4 | 7 | osimertinib 80 mg daily | 11.2 | true | MSS | 2026-03-15T05:36:01.844061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_899532 | REC_0016680 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 10.3 | 72 | female | 2 | 16 | 5.3 | 7 | alectinib 600 mg BID | 10.9 | true | MSS | 2026-03-15T05:36:01.844822+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167232 | REC_0016681 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 12.7 | 66 | female | 1 | 19 | 5.4 | 2 | osimertinib 80 mg daily | 18.2 | true | MSI-H | 2026-03-15T05:36:01.845234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_245251 | REC_0016682 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 10.2 | 72 | female | 3 | 14 | 3.7 | 2 | alectinib 600 mg BID | 20.9 | true | MSI-H | 2026-03-15T05:36:01.845633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792125 | REC_0016683 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.5 | 60 | male | 0 | 18 | 3.5 | 4 | entrectinib 600 mg daily | 11.2 | true | MSI-H | 2026-03-15T05:36:01.846004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629527 | REC_0016684 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 7.2 | 73 | female | 1 | 12 | 7.1 | 6 | sotorasib 960 mg daily | 7.4 | true | MSS | 2026-03-15T05:36:01.846381+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957736 | REC_0016685 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 30 | 7.3 | 68 | male | 1 | 57 | 3 | 4 | pembrolizumab 200 mg q3w | 17.4 | true | MSS | 2026-03-15T05:36:01.846765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692022 | REC_0016686 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.8 | 61 | male | 0 | 63 | 8 | 5 | pembrolizumab 200 mg q3w | 14 | true | MSS | 2026-03-15T05:36:01.847132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603623 | REC_0016687 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 11.6 | 56 | female | 1 | 17 | 6.3 | 4 | osimertinib 80 mg daily | 8.4 | true | MSS | 2026-03-15T05:36:01.847507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445755 | REC_0016688 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 21 | 16.5 | 66 | male | 0 | 0 | 4.7 | 2 | osimertinib 80 mg daily | 29.7 | true | MSI-H | 2026-03-15T05:36:01.847884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175544 | REC_0016689 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 5.5 | 64 | male | 0 | 5 | 4.2 | 4 | osimertinib 80 mg daily | 15.5 | false | MSS | 2026-03-15T05:36:01.848503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229046 | REC_0016690 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.2 | 66 | female | 1 | 6 | 5.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 15.4 | false | MSS | 2026-03-15T05:36:01.848940+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209101 | REC_0016691 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.5 | 72 | female | 2 | 19 | 4.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 9.7 | false | MSS | 2026-03-15T05:36:01.849340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957111 | REC_0016692 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.6 | 51 | male | 0 | 20 | 4.5 | 7 | sotorasib 960 mg daily | 13.4 | true | MSS | 2026-03-15T05:36:01.849727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697710 | REC_0016693 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 2.5 | 66 | male | 1 | 55 | 4.6 | 6 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:36:01.850314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386835 | REC_0016694 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 7.1 | 67 | female | 0 | 7 | 6.2 | 1 | osimertinib 80 mg daily | 11.3 | true | MSS | 2026-03-15T05:36:01.850689+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409158 | REC_0016695 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 29 | 14.8 | 73 | male | 1 | 13 | 5.7 | 0 | sotorasib 960 mg daily | 52.7 | true | MSI-H | 2026-03-15T05:36:01.851023+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984116 | REC_0016696 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.6 | 63 | female | 1 | 19 | 4.9 | 1 | sotorasib 960 mg daily | 25.8 | false | MSS | 2026-03-15T05:36:01.851366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448183 | REC_0016697 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 20 | 5.9 | 66 | male | 0 | 61 | 5.3 | 2 | pembrolizumab 200 mg q3w | 18.9 | false | MSS | 2026-03-15T05:36:01.851725+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998722 | REC_0016698 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.2 | 73 | female | 0 | 26 | 6 | 3 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:36:01.852146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130963 | REC_0016699 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.2 | 70 | female | 2 | 37 | 4.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.5 | true | MSS | 2026-03-15T05:36:01.852507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557054 | REC_0016700 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 18.7 | 75 | female | 1 | 15 | 5.8 | 4 | sotorasib 960 mg daily | 9.3 | false | MSS | 2026-03-15T05:36:01.852864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.